<DOC>
	<DOCNO>NCT02130024</DOCNO>
	<brief_summary>This study ass development Geographic Atrophy either ranibizumab aflibercept patient wet Age relate Macular Degeneration .</brief_summary>
	<brief_title>A Comparison Ranibizumab Aflibercept Development Geographic Atrophy ( Wet ) AMD Patients</brief_title>
	<detailed_description>This phase IV , randomise , control , mask study recruit patient one treatment-naïve eye present subfoveal choroidal neovascularisation ( CNV ) secondary wet AMD . At screen , follow informed consent process , patient assess study eligibility assessment visual acuity use logarithm minimum angle resolution ( logMAR ) , stereoscopic biomicroscopic slit-lamp fundus examination ( 78 D similar lens ) ; fluorescein angiogram ( FA ) ; colour fundus photography ; fundus autofluorescence optical coherence tomography ( OCT ) . Eligible patient enrol randomised one two arm : Arm 1 : 0.5 mg ranibizumab use inject extend regimen Arm 2 : 2.0 mg aflibercept use inject extend regimen .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion criterion study eye : Diagnosis active subfoveal CNV secondary wet AMD without restriction lesion size , visual impairment exclusively due active wet AMD lesion . Active lesion characterise follow : abnormal retinal thickness , evidence intraretinal , subretinal subpigment epithelial fluid accumulation , confirm OCT ; presence intraretinal subretinal haemorrhage ; leakage show FA unless solely due dry , fibrotic staining ; visual acuity deterioration consider likely represent CNV . BCVA score Screening Baseline must 23 letter measure 3 metre Early Treatment Diabetic Retinopathy Study ( ETDRS ) like chart , inclusively ( approximate Snellen equivalent 3/60+3 ) . Exclusion Criteria 1 . Inability comply study followup procedure . 2 . Pregnant nursing ( lactate ) woman . 3 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment . Exclusion criterion systemic medical history condition : 4 . Any type systemic disease treatment , include medical condition ( control uncontrolled ) could expect progress , recur , change extent may bias assessment clinical status patient significant degree put patient special risk . 5 . Stroke myocardial infarction le 3 month prior Screening . 6 . Uncontrolled blood pressure define systolic value &gt; 160 mm Hg diastolic value &gt; 100 mm Hg Screening Baseline . 7 . Known hypersensitivity ranibizumab aflibercept component ranibizumab aflibercept formulation , fluorescein . Exclusion criterion ocular medical history condition : For eye : 8 . Any active periocular ocular infection inflammation ( e.g. , blepharitis , conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) time Screening Baseline . 9 . 1 patch geographic atrophy &gt; 250µm long linear dimension . 10 . Uncontrolled glaucoma ( intraocular pressure [ IOP ] ≥30 mm Hg medication accord investigator 's judgment ) time Screening Baseline . 11 . Neovascularisation iris neovascular glaucoma time Screening Baseline . 12 . Inability obtain multimodal image sufficient quality analyse . For study eye : 13 . Visually significant cataract ( likely require surgery within next 12 month ) , aphakia , severe vitreous haemorrhage , rhegmatogenous retinal detachment , proliferative diabetic retinopathy CNV cause wet AMD ( e.g. , ocular histoplasmosis , pathologic myopia macular hole ) time Screening Baseline . 14 . Structural damage within 0.5 disc diameter centre macula ( e.g. , vitreomacular traction , epiretinal membrane , scar , laser burn , foveal atrophy ) time screen investigator 's opinion could preclude visual function improvement treatment . Exclusion criterion prior current systemic medication : 15 . Use investigational drug within 30 day 5 halflives baseline , whichever longer . 16 . Current plan use systemic medication know toxic lens , retina optic nerve outline Lucentis Eylea Product Information . Exclusion criterion prior current ocular treatment : For study eye : 17 . Treatment antiangiogenic drug ( include antiVEGF agent ) prior Baseline eye . 18 . Any intraocular procedure ( include YttriumAluminiumGarnet capsulotomy ) within 2 month prior Baseline anticipate within next 6 month follow Baseline . Exclusion criterion prohibit treatment ( study eye ) : 19 . Intra periocular corticosteroid ( include sub tenon exclude topical formulation ) 20 . Intraocular corticosteroid implant</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Age-related macular degeneration , ranibizumab , aflibercept , geographic atrophy , inject extend</keyword>
</DOC>